🚨KRAS is no longer undruggable.
DaraxonRASib shows OS 13.2 vs 6.7 months (HR 0.40, P<0.001) in pancreatic cancer.
👉 Press release: https://t.co/U5jinDgjom
@OncoAlert
Just out in @myESMO GO: our PANCAKE study🥞
🟣Diabetic patients with PDAC ➡️ longer OS with GemNabP, not FOLFIRINOX
This work is a testament to a growing community of young 🇮🇹researchers dedicated to #PDAC with rigorous science
@oncodaily@OncoDailyGI https://t.co/AuJ5dV53Eb
Day 1 at the ESMO Gastric Cancer Preceptorship 🇪🇸
Kicking off with powerful insights and great company. Grateful to @myESMO for the great organisation!
#ESMO#GastricCancer#Oncology#Day1#Madrid
Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real‐life worldwide population https://t.co/jxCcdRwyzO
Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer
@NEJM
https://t.co/b3W2cVQE9F
👉Trastuzumab deruxtecan significantly improved overall survival than ramucirumab paclitaxel
🧐Looking forward to the 1st line trials
@myESMO
Durvalumab + FLOT in resectable GC/GEJ cancer
#ASCO25 Plenary session
🔎MATTERHORN
👉mEFS n.r. vs 32.8, HR 0.71
👉mDFS n.r. vs 39.8 mo
👉OS n.r. in both arms, HR 0.78, not (yet) significant
👉pCR 19 vs 7%
🧐 Finally, ICI arrived in the peri-operative setting
@myESMO
Can we rely on peritoneal specimens for PD-L1 assessment? 🧐
The spatial and temporal heterogeneity of PD-L1 expression in mGEA is a critical issue!
Our paper now online on ESMO Gastrointestinal Oncology 👇🏼
https://t.co/Oza8ys8pgm
Our last paper…fantastic international collaboration
-CisGem durvalumab in BTC patients -666 patients: median OS of 15.1 months and median PFS of 8.2 months -The results confirmed the results achieved in the TOPAZ-1 trial
https://t.co/QmOW3dIN2u
#ESMOGI24 is coming to an end… an excellent first time! Science, networking and fun… highly recommendable! Now ready to bring energy and motivation to our daily life and patients. @VStudiale @p_ciracimd @myESMO #ESMOAmbassadors
So grateful and excited to have the opportunity to present at #ESMOGI24 our prospective study on the prognostic impact of mutKRAS cftDNA in BR and LA PDAC !
@myESMO
🔥PLENARY Session #ASCO24🔥
Perioperative chemotherapy (FLOT) to neoadjuvant chemoradiation (CROSS) in patients with adenocarcinoma of the esophagus
🔎 ESOPEC phase III trial, 438 patients
👉R0 180 vs 171
👉pCR 17 vs 10%
👉mOS 66 vs 37 mo
👉3yr OS: 57.4 vs 50.7%
🧐FLOT improves OS compared to CROSS
@myESMO